ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2828

Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up

Sejin Byun1, Seung Min Jung1, Sang-Won Lee2, Yong-Beom Park2 and Jason Jungsik Song2, 1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, 2Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: prognostic factors and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Even though the survival rate among SLE patients has improved over the past few decades, the mortality rate caused by the acute flare of the SLE is still high. On the other hand, next to no information is available on the prognostic factors related to operations. D-dimer (DD) is especially known to rise in a thrombotic event; the purpose of this research was to learn more on the relationship between the prognosis of admitted patients treated with SLE d/t acute flare and the change in DD.

Methods: The subject of this research was 57 SLE patients whose DD was measured more than 2 times during one’s admission. The division criteria of the groups was the amount of change in the of the first and last measured DD result. If the DD value decreased by more than 25% of the first value, the patient was designated as group A while if the value increased by more than 25%, the patient was put in group C. If the patient’s change of DD value was within 25% of the first value, the patient was put in group B. Then, the difference in clinical features between each group as well as between group A+B and group C was investigated. The hospitalizations of SLE patients for reasons other than for SLE disease flare such as obvious infection, malignancy and thromboembolism were all excluded.

Results: There was a statistically significant difference between groups A, B, and C in relation to Lupus Nephritis (LN) and hospitalization mortality. In addition, there was a statistically significant difference in LN, C4, anti-dsDNA, anti-Ro, and hospitalization mortality between group A+B and C. In other words, increased pattern of DD significantly correlates with poor prognosisin hospitalized patients with SLE flares. On the other hand, unlike what we had expected, no meaningful difference was observed between each group and the SLEDAI-2K score, which measures disease activity.

Conclusion: The changing pattern of the DD value is related to the mortality rate as well as the presence of LN of a patient admitted due to SLE flare. This could be used as an adjuctive factor to predict the prognosis of the admission period.

Variables

Pattern A (n=23)

Pattern B (n=15)

Pattern C (n=19)

P value

A vs B vs C

P value

A+B (n=38) vs C (n=19)

Demographics

Age, years (median, IQR)

41 (37-51)

41 (22-45)

50 (33-55)

Female/male, Female (%)

19/4 (92.6)

13/2 (86.6)

17/2 (89.5)

Clinical findings

Arthritis

7 (30.4)

5 (33.3)

3 (15.8)

New rash

2 (8.7)

2 (13.3)

3 (15.8)

Lupus nephritis

(urine protein > 0.5g/d)

12 (52.2)

7 (46.7)

16 (84.2)

< 0.05

< 0.001

Serositis

8 (34.8)

1 (6.7)

5 (26.3)

Oral ulcer

1 (4.3)

3 (20.0)

1 (5.3)

Abn.liver enz.

5 (21.7)

4 (26.7)

5 (26.3)

SLEDAI-2K

6 (4-11)

8 (6-17)

9 (7-10)

Laboratory results

1st d-dimer

1239 (557-6318)

485 (375-845)

463 (316-739)

WBC

6.80 (2.82-10.2)

6.29 (2.69-7.84)

5.73 (3.55-10.69)

Hb

10.2 (9.35-12.75)

10.9 (9.6-11.9)

9.2 (8.6-11.6)

PLT

110 (87-228)

125 (86-209)

162 (72-256)

ESR

43 (18-64)

43 (31-78)

43 (12-81)

CRP

43.0 (17.5-63.5)

15.2 (8.4-41.2)

10.4 (1.2-33.4)

C3

53.3 (37.8-81.7)

60.8 (23.6-81.8)

60.0 (49.6-90.5)

C4

11.2 (4.3-17.8)

8.1 (3.3-14.4)

13.8 (8.1-23.8)

< 0.05

Albumin

3.4 (2.9-3.7)

3.0 (2.3-3.4)

2.8 (2.4-3.4)

Serum Cr

0.71 (0.58-1.05)

0.72 (0.59-1.24)

0.78 (0.56-1.78)

LDH

438 (234-609)

278 (218-463)

505 (304-729)

ANA

23 (100)

15 (100)

18 (94.7)

Anti-dsDNA

17 (73.9)

13 (86.7)

10 (52.6)

< 0.05

Anti-Sm

3 (13.0)

5 (33.3)

8 (42.1)

Anti-Ro

7 (30.4)

8 (53.3)

13 (68.4)

< 0.05

Anti-La

2 (8.6)

5 (33.3)

4 (21.1)

Anti-RNP

7 (30.4)

7 (46.7)

8 (42.1)

LA

7 (30.4)

8 (53.3)

8 (42.1

aCL_IgM

6 (26.1)

5 (33.3)

6 (31.6)

aCL_IgG

9 (39.1)

4 (26.7)

2 (10.5)

< 0.05

β2GP_IgG

4 (17.4)

2 (13.3)

1 (5.3)

β2GP_IgM

3 (13.0)

1 (6.7)

0 (0)

Clinical outcomes

Hospitalization period

22 (11-49)

46 (17-73)

20 (12-31)

Mortality

3 (13.0)

3 (20.0)

8 (42.1)

< 0.05

< 0.05


Disclosure: S. Byun, None; S. M. Jung, None; S. W. Lee, None; Y. B. Park, None; J. J. Song, None.

To cite this abstract in AMA style:

Byun S, Jung SM, Lee SW, Park YB, Song JJ. Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/difference-of-d-dimer-between-two-time-points-predicts-prognosis-of-admitted-patients-with-sle-flare-up/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/difference-of-d-dimer-between-two-time-points-predicts-prognosis-of-admitted-patients-with-sle-flare-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology